The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The company will also share results in two additional posters for deuruxolitinib
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
